Zoetis Inc. ZTS

Full chart Compare
Set alert

Price alert · ZTS

All alert types
82.99 USD -0.19 (-0.23%)

At closeNov 3, 2026, 5:50 PM EST

82.80 -0.19 -0.23%

After hours · Nov 3, 5:50 PM ET

81.53 Day range 83.73
68.77 52-week range 132.49
YTD
-34.04%
1 year
-42.51%
Market cap
34.29B
Revenue (ttm)
9.53B
Profit margin
27.68%
EPS (ttm)
6.08
Shares out
413.22M
P/E ratio
13.65
Forward P/E
12.95
Dividend
2.12 (2.55%)
Ex-dividend date
Oct 29, 2026
YTD return
-34.04%
1-year return
-42.51%
Volume
3.70M
Avg volume
4.99M
Open
82.29
Previous close
83.18
Day's range
81.53 – 83.73
52-week range
68.77 – 132.49
Beta
0.68
Analysts
Hold
Price target
88.38 (+6.5%)
Earnings date
Nov 5, 2026

2Y -92.19 (-52.63%)

100150Jan 25Jun 25Nov 25Mar 26Aug 2682.99

Key statistics

Enterprise value
41.95B
PEG ratio
15.48
Price / sales
3.60
Price / book
10.92
Dividend yield
2.55%
Payout ratio
33.88%
Revenue growth
-0.20%
Free cash flow
2.02B
Total cash
1.68B
Total debt
9.26B
Return on equity
64.91%
Short % of float
4.80%
50-day average
75.16
200-day average
93.32

Financials — quick view

All financials
ZTS Revenue — quarterly 2.47B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ZTS Net income — quarterly 691.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ZTS EPS — quarterly 1.65
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ZTS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20261.51———
Aug 6, 2026Jun 30, 20261.851.87+0.02+1.08%
May 7, 2026Mar 31, 20261.601.53-0.07-4.38%
Feb 12, 2026Dec 31, 20251.401.48+0.08+5.71%
Nov 4, 2025Sep 30, 20251.621.70+0.08+4.94%
Aug 5, 2025Jun 30, 20251.621.76+0.14+8.64%

Upgrades / downgrades

ZTS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Morgan StanleymainOverweightOverweight
Oct 27, 2026UBSmainNeutralNeutral
Oct 20, 2026JefferiesdownBuyHold
Oct 16, 2026Goldman Sachsinit—Neutral
Aug 25, 2026TD CowenmainBuyBuy
Aug 20, 2026StifelmainHoldHold

About Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
zoetis.com

News

Your note

Sign in to keep a note on ZTS — it syncs with the Stock Master app.

Insider holders

ZTS insider holders
InsiderRelationLatest transactionDateShares held
BISARO PAUL M.DirectorPurchaseMay 12, 202627,862
D AMELIO FRANK ADirectorPurchaseMay 12, 202621,458
JOSEPH WETTENYChief Financial OfficerConversion of Exercise of derivative securityFeb 5, 202620,766
LAGANO ROXANNEOfficerConversion of Exercise of derivative securityFeb 18, 202616,465
MCCALLISTER MICHAEL BDirectorStock GiftJun 9, 202631,893
NORDEN GREGORYDirectorStock GiftMar 8, 202618,167

Institution ownership

ZTS institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.54%39,430,1813.27BJun 29, 2026
Vanguard Capital Management LLC6.30%26,027,9842.16BJun 29, 2026
Vanguard Portfolio Management LLC5.77%23,860,4451.98BJun 29, 2026
State Street Corporation4.76%19,667,7231.63BJun 29, 2026
State Farm Mutual Automobile Insurance Co3.85%15,892,9031.32BJun 29, 2026
Geode Capital Management, LLC3.22%13,289,6221.10BJun 29, 2026

Fund ownership

ZTS fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.90%11,982,269994.35MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.63%10,862,724901.44MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund1.98%8,175,936678.48MJun 29, 2026
VANGUARD FENWAY FUNDS-Vanguard Equity Income Fund1.48%6,106,220506.72MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%5,506,516456.96MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.32%5,441,955451.60MAug 30, 2026